Henagliflozin
Modify Date: 2024-04-09 18:41:41
Henagliflozin structure
|
Common Name | Henagliflozin | ||
|---|---|---|---|---|
| CAS Number | 1623804-44-3 | Molecular Weight | 454.87 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H24ClFO7 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of HenagliflozinHenagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research[1]. |
| Name | Henagliflozin |
|---|
| Description | Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Henagliflozin (SHR3824) (p.o., 0.1-3.0 mg/kg, once) 可以以剂量依赖的方式改善了正常小鼠的暴露于葡萄糖挑战后的葡萄糖耐量[1]。 Henagliflozin (SHR3824) (p.o.,0.3-3.0 mg/kg, once daily, 41 days）以剂量依赖的方式增加尿糖排泄，可显着降低 GK 大鼠的血糖水平，对体重和食物摄入无影响。且用 0.3、1.0 或 3.0 mg/kg 剂量处理的 GK 大鼠的 HbA1c 值分别为 5.47%、5.19% 和 5.04%[1]。 Henagliflozin (SHR3824) (p.o.,0.3-3.0 mg/kg, once daily, 43 days）导致 db/db小鼠尿量和尿糖排泄呈剂量依赖性增加，同时血浆葡萄糖水平降低，对体重和食物摄入无影响。并且在 0.3、1.0 或 3.0 mg/kg 的剂量下，导致小鼠非空腹和空腹血糖水平分别显着降低 24.7%、28.2% 或 35.1% 和 49.5%、57.8% 或 62.9%[1]。 |
| References |
| Molecular Formula | C22H24ClFO7 |
|---|---|
| Molecular Weight | 454.87 |